R37AI116550

Defining the pathways activated by Toll-like receptors to stimulate immunity - Project Summary

The goal of this proposal is to identify how Toll-like receptors (TLRs) stimulate diverse cellular responses in macrophages and dendritic cells (DCs), and to understand how these responses influence DC-based cancer immunotherapies.

The ability of TLRs to induce inflammatory gene expression has been under investigation for twenty years, with distinct signaling pathways mediated by the MYD88 and TRIF adaptors explaining all transcriptional responses. It has only recently become appreciated that TLRs also drive metabolic changes in responding cells, such as the rapid induction of aerobic glycolysis.

During the previous funding period, we discovered that the TLR-induced MYDDOSOME complex contains two classes of proteins. One class is necessary for MYDDOSOME assembly (e.g. MYD88) and represents the core of this signaling structure. The second class is not necessary for MYDDOSOME assembly (e.g. TRAF6), but rather operates to recruit enzymes that diversify the effector functions of the MYDDOSOME. Specifically, we identified the kinase TBK1 as a MYDDOSOME component that is recruited by TRAF6 and is dedicated specifically to induce glycolysis. The MYDDOSOME therefore serves as a subcellular site of signals that activate diverse cellular responses. Our understanding of how these activities are regulated in vitro and their impact on T cell-mediated protective immunity remains limited.

In addition to the MYDDOSOME, select TLRs (e.g. TLR4 and TLR3) engage the TRIFFOSOME. The central TRIFFOSOME regulator is TRIF, which stimulates interferon (IFN) responses, NF-KB and MAPK activation, necroptosis, and glycolysis. While the importance of TRIF in immunity has long been recognized, the means by which it activates these diverse responses is unclear. This gap in knowledge is not merely an academic curiosity, as TRIF is essential for the ability of the LPS receptor TLR4 to stimulate adaptive immunity. Understanding regulatory events that stimulate MYDDOSOME- and TRIF-dependent responses will enable discussions of how TLRs drive protective immunity against infection and cancer.

In this application, we propose to explore MYDDOSOME activities in vitro and in the context of cancer immunotherapies (Aim 1). In Aim 2, we offer an innovative synthetic biology-based approach to define the mechanisms of TRIF signaling and how these mechanisms relate to those induced by complementary innate immune pathways. Our focus on the two major signaling pathways activated by TLRs should provide an operational view of this important family of receptors.

Children's Hospital Corporation

NOT APPLICABLE

93.855 - Allergy and Infectious Diseases Research

National Institute of Allergy and Infectious Diseases (NIAID) [HHS - NIH]

Boston, Massachusetts 021155724 United States

Single Zip Code

NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed) (PA-20-185)

Amendment Since initial award the End Date has been extended from 01/31/26 to 04/30/31 and the total obligations have increased 521% from $531,000 to $3,295,800.